IVIG Treatment in Post-polio Patients: Evaluation of Responders

Overview

Journal J Neurol

Specialty Neurology

Date 2012 May 18

PMID 22592288

Citations 5

Authors

Gunilla Ostlund

Lisbet Broman

Lars Werhagen

Kristian Borg

Affiliations

Soon will be listed here.

Abstract

The aim of this work is to evaluate the outcome of IVIG treatment in patients with post-polio syndrome (PPS) and to identify responders. The study included 113 PPS patients who had received one IVIG treatment in an open trial, prospective follow-up study. Clinical examination was performed and clinical data were retrieved from medical records. The short form 36 (SF-36), physical activity scale for the elderly (PASE), and the visual analogue scale (VAS) were used as measurements of quality of life, physical activity, and the intensity of pain. Data before treatment and at 6-month follow-up were collected. Analysis was performed in subgroups based on demographic and medical parameters. A statistically significant increase of the SF-36 sub domains bodily pain, vitality, social function, role emotional, and the mental compound score (MCS) was found at the 6-month follow-up. A significant decrease of pain was found in patients who reported pain intensity over VAS of 20 mm, in patients younger than 65 years of age and in patients who had paresis in the lower extremities. A trend was found in patients with PPS as the only diagnosis. IVIG leads to increase of quality of life at 6-month follow-up for SF-36 regarding sub domains of bodily pain, vitality, social function, role emotional, as well as for pain. Age below 65 years, paresis in the lower extremities, and lack of concomitant disorders may be the main indicators for a future identification of responders.

Citing Articles

Prevalence and Severity of Central Sensitization in Post-Polio Syndrome: Associations with Clinical Measures and Quality of Life.

On A, Latifoglou E, Cinar E, Tanigor G Ann Indian Acad Neurol. 2024; 27(3):282-288.

PMID: 38907687 PMC: 11232829. DOI: 10.4103/aian.aian_1040_23.

Post-polio syndrome is not a dysimmune condition.

Laffont I, Duflos C, Hirtz C, Bakhti K, Gelis A, Palayer C Eur J Phys Rehabil Med. 2024; 60(2):270-279.

PMID: 38252127 PMC: 11112507. DOI: 10.23736/S1973-9087.23.08158-3.

Post-polio Syndrome: More Than Just a Lower Motor Neuron Disease.

Shing S, Chipika R, Finegan E, Murray D, Hardiman O, Bede P Front Neurol. 2019; 10:773.

PMID: 31379723 PMC: 6646725. DOI: 10.3389/fneur.2019.00773.

Survey of young patients with polio and a foreign background at a Swedish post-polio outpatient clinic.

Werhagen L, Borg K Neurol Sci. 2016; 37(10):1597-601.

PMID: 27299427 DOI: 10.1007/s10072-016-2629-3.

Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis.

Huang Y, Chen H, Huang K, Chen P, Hu C, Tsai C BMC Neurol. 2015; 15:39.

PMID: 25886512 PMC: 4379590. DOI: 10.1186/s12883-015-0301-9.

References

Price D, Finniss D, Benedetti F . A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2007; 59:565-90. DOI: 10.1146/annurev.psych.59.113006.095941. View

Kaponides G, Gonzalez H, Olsson T, Borg K . Effect of intravenous immunoglobulin in patients with post-polio syndrome -- an uncontrolled pilot study. J Rehabil Med. 2006; 38(2):138-40. DOI: 10.1080/16501970500441625. View

Melnick J . Current status of poliovirus infections. Clin Microbiol Rev. 1996; 9(3):293-300. PMC: 172894. DOI: 10.1128/CMR.9.3.293. View

Jensen M, Alschuler K, Smith A, Verrall A, Goetz M, Molton I . Pain and fatigue in persons with postpolio syndrome: independent effects on functioning. Arch Phys Med Rehabil. 2011; 92(11):1796-801. DOI: 10.1016/j.apmr.2011.06.019. View

Sullivan M, Karlsson J, Ware Jr J . The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995; 41(10):1349-58. DOI: 10.1016/0277-9536(95)00125-q. View

Washburn R, McAuley E, Katula J, Mihalko S, Boileau R . The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol. 1999; 52(7):643-51. DOI: 10.1016/s0895-4356(99)00049-9. View

Trojan D, Cashman N . Post-poliomyelitis syndrome. Muscle Nerve. 2004; 31(1):6-19. DOI: 10.1002/mus.20259. View

JOYCE C, Zutshi D, HRUBES V, Mason R . Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975; 8(6):415-20. DOI: 10.1007/BF00562315. View

Farbu E, Gilhus N, Barnes M, Borg K, de Visser M, Driessen A . EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol. 2006; 13(8):795-801. DOI: 10.1111/j.1468-1331.2006.01385.x. View

10.

Gonzalez H, Sunnerhagen K, Sjoberg I, Kaponides G, Olsson T, Borg K . Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 2006; 5(6):493-500. DOI: 10.1016/S1474-4422(06)70447-1. View

11.

Sullivan M, Karlsson J . The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol. 1998; 51(11):1105-13. DOI: 10.1016/s0895-4356(98)00102-4. View

12.

Gonzalez H, Ottervald J, Nilsson K, Sjogren N, Miliotis T, von Bahr H . Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics. 2008; 71(6):670-81. DOI: 10.1016/j.jprot.2008.11.014. View

13.

Borg K . Post-polio muscle dysfunction 29th ENMC workshop 14-16 October 1994, Naarden, the Netherlands. Neuromuscul Disord. 1996; 6(1):75-80. DOI: 10.1016/0960-8966(95)00013-5. View

14.

Gonzalez H, Olsson T, Borg K . Management of postpolio syndrome. Lancet Neurol. 2010; 9(6):634-42. DOI: 10.1016/S1474-4422(10)70095-8. View

15.

Huskisson E . Measurement of pain. Lancet. 1974; 2(7889):1127-31. DOI: 10.1016/s0140-6736(74)90884-8. View

16.

Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus N, Aarli J . Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol. 2007; 14(1):60-5. DOI: 10.1111/j.1468-1331.2006.01552.x. View

17.

Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T . Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci. 2002; 205(1):9-13. DOI: 10.1016/s0022-510x(02)00316-7. View

18.

Werhagen L, Borg K . Effect of intravenous immunoglobulin on pain in patients with post-polio syndrome. J Rehabil Med. 2011; 43(11):1038-40. DOI: 10.2340/16501977-0884. View

19.

Fordyce C, Gagne D, Jalili F, Alatab S, Arnold D, Da Costa D . Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci. 2008; 271(1-2):80-6. DOI: 10.1016/j.jns.2008.03.015. View

20.

Gonzalez H, Khademi M, Andersson M, Piehl F, Wallstrom E, Borg K . Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol. 2004; 150(1-2):139-44. DOI: 10.1016/j.jneuroim.2004.01.010. View